Abstract
AbstractHomozygous or compound heterozygous (biallelic) variants in PRKN are causal for PD with highly penetrant symptom expression, while the much more common heterozygous variants may predispose to PD with highly reduced penetrance, through altered mitochondrial function. In the presence of pathogenic heterozygous variants, it is therefore important to test for mitochondrial alteration in cells derived from variant carriers to establish potential presymptomatic molecular markers. We generated lymphoblasts (LCLs) and human induced pluripotent stem cell (hiPSC)-derived neurons from non-manifesting heterozygous PRKN variant carriers and tested them for mitochondrial functionality. In LCLs, we detected hyperactive mitochondrial respiration, and, although milder compared to a biallelic PRKN-PD patient, hiPSC-derived neurons of non-manifesting heterozygous variant carriers also displayed several phenotypes of altered mitochondrial function. Overall, we identified molecular phenotypes that might be used to monitor heterozygous PRKN variant carriers during the prodromal phase. Such markers might also be useful to identify individuals at greater risk of eventual disease development and for testing potential mitochondrial function-based neuroprotective therapies before neurodegeneration advances.
Funder
Fonds National de la Recherche Luxembourg
Provincia Autonoma di Bolzano - Alto Adige
Deutsche Forschungsgemeinschaft
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Neurology (clinical),Neurology
Reference91 articles.
1. Bloem, B. R., Okun, M. S. & Klein, C. Parkinson’s disease. Lancet. https://doi.org/10.1016/S0140-6736(21)00218-X (2021).
2. Kouli, A., Torsney, K. M. & Kuan, W. L. In Parkinson’s Disease: Pathogenesis and Clinical Aspects (eds Stoker, T. B. & Greenland, J. C.) Ch. 1, (Codon Publications, 2018).
3. Forno, L. S. Neuropathology of Parkinson’s disease. J. Neuropathol. Exp. Neurol. 55, 259–272 (1996).
4. Moustafa, A. A. et al. Motor symptoms in Parkinson’s disease: a unified framework. Neurosci. Biobehav. Rev. 68, 727–740 (2016).
5. Blauwendraat, C., Nalls, M. A. & Singleton, A. B. The genetic architecture of Parkinson’s disease. Lancet Neurol. 19, 170–178 (2020).
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献